Disc Medicine, Inc. 8-K

What Happened Disc Medicine, Inc. (IRON) filed an 8-K on June 24, 2026 reporting the results of its June 18, 2026 Annual Meeting of Stockholders. Stockholders elected three Class III directors—Donald Nicholson, Ph.D., John Quisel, J.D., Ph.D., and William White, M.P.P., J.D.—each to a three‑year term expiring in 2029. Shareholders also approved, on a non‑binding advisory basis, the company’s named executive officer compensation (say‑on‑pay), and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The company’s definitive proxy was filed April 28, 2026.

Key Details

• Director elections (Class III, term to 2029):
  • Donald Nicholson: 28,559,799 For; 5,347,450 Withheld; 2,011,469 Broker non‑votes.
  • John Quisel: 33,433,078 For; 474,171 Withheld; 2,011,469 Broker non‑votes.
  • William White: 33,355,406 For; 551,843 Withheld; 2,011,469 Broker non‑votes.
• Say‑on‑pay (advisory): 33,528,449 For; 368,970 Against; 9,830 Abstain; 2,011,469 Broker non‑votes.
• Auditor ratification: Ernst & Young LLP ratified with 35,908,900 For; 1,298 Against; 8,520 Abstain.
• 8‑K filed and signed by President & CEO John Quisel on June 24, 2026.

Why It Matters These votes confirm the company’s board composition and governance direction through 2029 and indicate shareholder support for the company’s disclosed executive pay policies (though the compensation vote is non‑binding). Ratification of EY as auditor provides continuity for financial reporting oversight for fiscal 2026. For investors, the filing signals governance stability and no immediate changes to management, board control, or external audit provider based on the meeting outcomes.